Suppr超能文献

按照欧洲变态反应和临床免疫学会(EAACI)/全球变态反应和哮喘欧洲网络(GA(2)LEN)/欧洲皮肤病学论坛(EDF)/世界变态反应组织(WAO)指南在常规临床实践中对慢性自发性荨麻疹的管理

Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines.

作者信息

Marín-Cabañas I, Berbegal-de Gracia L, de León-Marrero F, Hispán P, Silvestre J F

机构信息

Servicio de Dermatología, Hospital General Universitario de Elda, Elda, Alicante, España.

Servicio de Dermatología, Hospital General Universitario de Alicante, Alicante, España.

出版信息

Actas Dermosifiliogr. 2017 May;108(4):346-353. doi: 10.1016/j.ad.2016.12.012. Epub 2017 Feb 20.

Abstract

INTRODUCTION

Chronic spontaneous urticaria is a prevalent and difficult-to-treat condition that has a very negative impact on patient quality of life.

OBJECTIVE

To describe the epidemiological and clinical characteristics of patients presenting with chronic spontaneous urticaria and the response to treatment administered according to the EAACI/GA(2)LEN/EDF/WAO consensus guideline.

MATERIAL AND METHOD

Descriptive cross-sectional study of all the patients with chronic spontaneous urticaria who consulted a skin allergy unit in the dermatology department of a tertiary hospital in Spain between July 2011 and July 2015.

RESULTS

The study included 100 patients with chronic spontaneous urticaria; inducible urticaria was present in 43% of cases, and angioedema in 40%. On diagnosis, 53% of patients were taking nonsteroidal anti-inflammatory drugs. All patients were treated with second generation H1-antihistamines, but the standard dose was sufficient in only 18% of cases. Higher doses (up to 4 times the standard dose) achieved control of the urticaria in 74% of the patients studied. Higher doses of second generation H1-antihistamines were required to control the condition in patients with angioedema, and the presence of angioedema was associated with a lack of response to treatment with these drugs (OR, 6.1%; P<.001). One in 4 patients failed to respond to second generation H1-antihistamines and required treatment with omalizumab or ciclosporin to control their condition.

CONCLUSIONS

Doses of H1-antihistamines higher than the standard dose are required in most cases to achieve control of chronic spontaneous urticaria. Angioedema is associated with failure to respond to treatment with antihistamines. In refractory cases, control of the condition can be achieved with omalizumab or ciclosporin. Patients with chronic spontaneous urticaria do not generally avoid the use of nonsteroidal anti-inflammatory agents.

摘要

引言

慢性自发性荨麻疹是一种常见且难以治疗的疾病,对患者的生活质量有非常负面的影响。

目的

描述慢性自发性荨麻疹患者的流行病学和临床特征,以及根据欧洲变态反应和临床免疫学会(EAACI)/全球变态反应和临床免疫学会(GA)(2)LEN/欧洲皮肤病学联合会(EDF)/世界变态反应组织(WAO)共识指南进行治疗的反应。

材料与方法

对2011年7月至2015年7月期间在西班牙一家三级医院皮肤科的皮肤过敏科就诊的所有慢性自发性荨麻疹患者进行描述性横断面研究。

结果

该研究纳入了100例慢性自发性荨麻疹患者;43%的病例存在诱导性荨麻疹,40%存在血管性水肿。诊断时,53%的患者正在服用非甾体类抗炎药。所有患者均接受第二代H1抗组胺药治疗,但标准剂量仅在18%的病例中足够。更高剂量(高达标准剂量的4倍)使74%的研究患者的荨麻疹得到控制。血管性水肿患者需要更高剂量的第二代H1抗组胺药来控制病情,并且血管性水肿的存在与这些药物治疗反应不佳相关(比值比,6.1%;P<0.001)。四分之一的患者对第二代H1抗组胺药无反应,需要用奥马珠单抗或环孢素治疗以控制病情。

结论

在大多数情况下,需要高于标准剂量的H1抗组胺药来控制慢性自发性荨麻疹。血管性水肿与抗组胺药治疗反应不佳相关。在难治性病例中,使用奥马珠单抗或环孢素可控制病情。慢性自发性荨麻疹患者通常不会避免使用非甾体类抗炎药。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验